Unlock instant, AI-driven research and patent intelligence for your innovation.

Novel malaria whole worm inactivated vaccine with preventing and treating effects

A technology for vaccines and malaria, which is applied in the field of new-type inactivated malaria whole-worm vaccines, can solve the problems of large dosage, and achieve the effects of simple preparation, immune response regulation and enhanced effect

Inactive Publication Date: 2016-02-03
ARMY MEDICAL UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the protective effect of the inactivated vaccine of the whole erythrocystis is not very ideal, and the dosage is relatively large, so it is urgent to further optimize and perfect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel malaria whole worm inactivated vaccine with preventing and treating effects
  • Novel malaria whole worm inactivated vaccine with preventing and treating effects
  • Novel malaria whole worm inactivated vaccine with preventing and treating effects

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Preparation of embodiment 1 inactivated whole worm vaccine

[0026] Firstly, the parasite antigen is prepared, and the preparation process is as follows:

[0027] Resuscitate the Plasmodium NSM strains stored in liquid nitrogen, then infect 30 Balb / c mice with the resuscitated NSM, and collect NSM parasites as parasites when the parasitemia reaches about 50% on the 4th day and the 9th day after infection, respectively. body antigen. The main process of the parasite antigen acquisition process is as follows: the blood components of the mouse are obtained by taking blood from the heart, and added to a centrifuge tube containing heparin to avoid coagulation; the above blood cells are washed 3 times with PBS with a pH value of 7.4 and a concentration of 0.1mol / L After heparin was removed, saponin with a final concentration of 0.5% was added to lyse red blood cells to release intracellular parasite antigens; the above components were washed 5 times with PBS to remove heme a...

Embodiment 2

[0029] Example 2 Novel inactivated whole worm vaccine enhances the protection against red inner stage of malaria

[0030] The inactivated whole worm vaccine prepared in Example 1 was used to immunize mice with 1×10 8 The mice were subcutaneously immunized with a dose of Plasmodium per mouse, and the immunization was repeated twice every other week. The untreated mice were used as the blank control; after the last immunization, 1 × 10 6 Each challenged the mice of the blank control group and the experimental group, took blood smears for 48 hours to observe the immune protection effect of the mice, and counted and analyzed the protozoaemia of the mice. Statistical results such as figure 1 As shown, the blank control was subjected to 1×10 6 After a erythrocytic Plasmodium challenged, its parasitemia was at a high level all the time, and when the parasitemia was 30-40%, the mice all died, while its parasitemia of the inactivated whole worm vaccine group in Example 1 was at a hig...

Embodiment 3

[0031] Example 3 Novel inactivated whole worm vaccine enhances the protection to the infrared stage of malaria

[0032] The method described in Example 2 was used to immunize mice with the inactivated whole worm vaccine. The mice in the control group were not immunized. After the last immunization, the mice in the control group and the experimental group were challenged with 5000 Plasmodium parasites in the infrared stage, and the liver was taken after 42 hours. Quantitative detection of insect load, the results are as follows figure 2 As shown, compared with the control group, the hepatic stage worm load in the inactivated whole worm vaccine group decreased by about 50%. Immunity effect (statistically significant).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel malaria whole worm inactivated vaccine with preventing and treating effects. The vaccine is prepared by taking plasmodium body components in an inactivated erythrocytic stage as antigen and chloroquine as an adjuvant, and has a protective effect on both exo-erythrocytic stage and erythrocytic stage. The malaria vaccine disclosed by the invention takes inactivated whole worm bodies as the antigen, is richer in antigen type, adopts an antimalarial chloroquine as the adjuvant, and can achieve the effects of regulating immune reaction and enhancing the vaccine effect.

Description

technical field [0001] The invention relates to a malaria vaccine, in particular to a novel inactivated whole malaria malaria vaccine with prognostic effect. Background technique [0002] Malaria is a global insect-borne infectious disease caused by Plasmodium that seriously endangers human health. It is one of the three major infectious diseases together with tuberculosis and AIDS. According to a report released by the WHO, malaria is still spreading in 99 countries and regions. About 216 million people are infected with malaria every year, and 655,000 of them die. In order to control and eliminate malaria and reduce the mortality rate of children in Africa, the member states of the United Nations proposed in the "United Nations Millennium Development Goals" jointly signed by the United Nations to curb and begin to reverse the increase in the incidence of malaria on a global scale, and try to eliminate malaria in some countries The goal. [0003] Antimalarial drugs and mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/015A61K39/39A61P33/06
CPCY02A50/30
Inventor 徐文岳卢潇
Owner ARMY MEDICAL UNIV